A Post Authorization Registry Study of Participants Treated With LEQEMBI
← catalyst calendarNCT07762092 · readout in 3,513 d
Sponsored by Eisai Limited (industry) · 4523.T — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
400estimated
Sites
11
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | estimated | When the study began enrolling |
| Primary completion | 2036-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-04-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimers Disease
Intervention
- Other: No Intervention
Primary outcome
what the primary-completion date above is the date OFIncidence and Severity of Known AEs
measured Up to 3 years
Permalink · 4523.T's whole pipeline · Catalyst calendar · Every registered study · What changed